Form 4: MiMedx Group Executive Receives Stock and Option Grants

Ricci S. Whitlow, Chief Operating Officer of MiMedx Group, received grants of restricted stock and stock options on March 1, 2024.

Summary

• Ricci S. Whitlow, the Chief Operating Officer of MiMedx Group, Inc. (MDXG), reported changes in beneficial ownership of securities.
• On March 1, 2024, Whitlow was granted 58,478 shares of restricted stock, which vest fully on the third anniversary of the grant, subject to continued employment.
• Additionally, Whitlow received options to purchase 70,755 shares of common stock at an exercise price of $8.63, vesting 25% annually from the grant date, also contingent on continued employment.
• Following these transactions, Whitlow directly owns 459,528 shares of common stock and options for 70,755 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of executive compensation. The grants themselves are a positive sign of incentivizing management, but the document is purely informational.

Positives

• The grant of restricted stock and stock options to the COO suggests an incentive alignment with the company's long-term performance.
• The vesting schedules tied to continued employment may encourage retention of key personnel.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the granted securities.

Industry Context

Stock and option grants are a common practice in the biotech and medical device industries to incentivize and retain key executives. The specific terms of the grant (vesting schedule, exercise price) are typically benchmarked against industry standards and the company's performance.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the medical device industry.
• Companies like Stryker, Medtronic, and Boston Scientific also utilize stock options and restricted stock units to incentivize their executives.
• The vesting schedule of 25% per year is a common practice, aligning with industry norms for executive retention.
• The specific value of the grant as a percentage of salary would need to be compared to peer companies to assess its competitiveness.

Stakeholder Impact

• Shareholders may view the grants as a positive incentive for management to drive company performance.
• Employees may see the grants as a sign of the company's commitment to its leadership.

Key Dates